BGX

BGX – BLACK GOLD EXPLORATION CORP ANNOUNCES EQUITY INCENTIVE GRANT AND DEBT SETTLEMENT AGREEMENTS

Retrieved on: 
Friday, March 8, 2024

The Options granted to directors vest 20% on grant and 40% on the first and second anniversary of the grant date.

Key Points: 
  • The Options granted to directors vest 20% on grant and 40% on the first and second anniversary of the grant date.
  • The Options granted to Officers vest 20% on grant and 20% on the first, second, third and fourth anniversary of the grant date.
  • The Options and PSUs are granted in accordance with the Company's equity incentive plan adopted by BGX’s board of directors on March 7, 2024 (the "Equity Incentive Plan").
  • The maximum number of equity incentives available for grant is 20% of the Company’s Common Shares on a rolling basis.

A Global Milestone in Innovative Pancreatic Cancer Therapy

Retrieved on: 
Thursday, March 7, 2024

TAIPEI, March 6, 2024 /PRNewswire/ -- BioGate Precision Medicine Corp., a member of Powerchip Group, held a press conference today to unveil an innovative breakthrough in pancreatic cancer drug development. Dr. Frank Huang, Chairman and CEO of BioGate, revealed that BioGate through in-house R&D has created a targeted therapy biologic, BGX. This was achieved by developing multi-platform technology combining biochemistry, immunology, and molecular biology. Studies of animals implanted with human pancreatic cancer cells confirm BGX's efficacy in inhibiting tumor growth and antiproliferation in metastasis, while extending survival rates. This achievement represents a major global milestone in pancreatic cancer treatment. BioGate also announced its plan to apply for TFDA Phase I clinical trials and to seek approval from the U.S. FDA, offering hope and improved care for pancreatic cancer patients in Taiwan region as well as worldwide.

Key Points: 
  • Suppression of pancreatic cancer and increased survival rates in animals implanted with human pancreatic cancer cells when treated with biologic agent BGX, a proprietary targeted therapy developed in-house by BioGate.
  • Studies of animals implanted with human pancreatic cancer cells confirm BGX's efficacy in inhibiting tumor growth and antiproliferation in metastasis, while extending survival rates.
  • This achievement represents a major global milestone in pancreatic cancer treatment.
  • In studies of animals implanted with human cancer cells, BGX successfully inhibited the growth and spread of pancreatic cancer cells and prolonged survival rates.

A Global Milestone in Innovative Pancreatic Cancer Therapy

Retrieved on: 
Thursday, March 7, 2024

TAIPEI, March 7, 2024 /PRNewswire/ -- BioGate Precision Medicine Corp., a member of Powerchip Group, held a press conference today to unveil an innovative breakthrough in pancreatic cancer drug development. Dr. Frank Huang, Chairman and CEO of BioGate, revealed that BioGate through in-house R&D has created a targeted therapy biologic, BGX. This was achieved by developing multi-platform technology combining biochemistry, immunology, and molecular biology. Studies of animals implanted with human pancreatic cancer cells confirm BGX's efficacy in inhibiting tumor growth and antiproliferation in metastasis, while extending survival rates. This achievement represents a major global milestone in pancreatic cancer treatment. BioGate also announced its plan to apply for TFDA Phase I clinical trials and to seek approval from the U.S. FDA, offering hope and improved care for pancreatic cancer patients in Taiwan region as well as worldwide.

Key Points: 
  • Suppression of pancreatic cancer and increased survival rates in animals implanted with human pancreatic cancer cells when treated with biologic agent BGX, a proprietary targeted therapy developed in-house by BioGate.
  • Studies of animals implanted with human pancreatic cancer cells confirm BGX's efficacy in inhibiting tumor growth and antiproliferation in metastasis, while extending survival rates.
  • This achievement represents a major global milestone in pancreatic cancer treatment.
  • In studies of animals implanted with human cancer cells, BGX successfully inhibited the growth and spread of pancreatic cancer cells and prolonged survival rates.

Blackstone Credit Closed-End Funds Announce Trustee and Officer Changes

Retrieved on: 
Thursday, January 4, 2024

NEW YORK, Jan. 4, 2024 /PRNewswire/ -- Blackstone Liquid Credit Strategies LLC, an affiliate of Blackstone Alternative Credit Advisors LP (collectively, and together with their affiliates in the credit-focused business of Blackstone, Inc., "Blackstone Credit"), announced certain changes in Trustee and Officer positions for the three listed closed-end funds it advises, Blackstone Senior Floating Rate 2027 Term Fund (NYSE: BSL), Blackstone Long-Short Credit Income Fund (NYSE: BGX) and Blackstone Strategic Credit 2027 Term Fund (NYSE: BGB) (each a "Fund" and together the "Funds").

Key Points: 
  • NEW YORK, Jan. 4, 2024 /PRNewswire/ -- Blackstone Liquid Credit Strategies LLC, an affiliate of Blackstone Alternative Credit Advisors LP (collectively, and together with their affiliates in the credit-focused business of Blackstone, Inc., "Blackstone Credit"), announced certain changes in Trustee and Officer positions for the three listed closed-end funds it advises, Blackstone Senior Floating Rate 2027 Term Fund (NYSE: BSL), Blackstone Long-Short Credit Income Fund (NYSE: BGX) and Blackstone Strategic Credit 2027 Term Fund (NYSE: BGB) (each a "Fund" and together the "Funds").
  • Mr. Zable is a Senior Managing Director and the Global Head of Liquid Credit Strategies at Blackstone Credit, as well as a Portfolio Manager of the Funds.
  • Mr. Post is a Managing Director and Portfolio Manager at Blackstone Credit, including a Portfolio Manager of the Funds and Blackstone Credit's U.S. CLOs.
  • There will be no changes to the Funds' strategies, investment objectives or policies as a result of these changes.

Xebec Announces Q1 2022 Financial Results

Retrieved on: 
Thursday, May 12, 2022

As of April 2022, the number of outstanding quotes in Q1 2022 are approximately double the number from the same period last year.

Key Points: 
  • As of April 2022, the number of outstanding quotes in Q1 2022 are approximately double the number from the same period last year.
  • Q1 2022 saw a Gas-as-a-Service hydrogen generation project with Messer Group in the Czech Republic commissioned for two end users.
  • The Support segment, now being rebranded under XBC Flow Services, delivered solid results in Q1 2022 but felt the impacts of supply chain constraints, increased logistics costs and continued COVID-19 restrictions.
  • This press release refers to financial measures that are not recognized under International Financial Reporting Standard (IFRS).

Xebec Acquires Colorado-based UECompression to Establish North America’s Leading Renewable Natural Gas and Hydrogen Manufacturing Facility

Retrieved on: 
Wednesday, November 3, 2021

MONTREAL, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Xebec Adsorption Inc. (TSX: XBC) (“Xebec”), a global provider of clean energy solutions, is pleased to announce today that it has closed the acquisition of all the outstanding shares of Colorado-based UECompression (“UEC”). Founded in 1983, UEC is a premier designer and builder of custom air and gas compressor solutions for power generation, industrial and energy applications.

Key Points: 
  • The acquisition of UEC provides Xebec with a cost-effective and timely pathway towards expanding production capacity five-fold for standardized renewable gas systems while supporting UECs legacy business as the operation continues its energy transition.
  • In addition, Xebecs global manufacturing footprint is further optimized by bringing European gas generation products such as Hy.GEN to the U.S. and focuses UECs facility on containerized and skid-mounted renewable energy systems.
  • UEC helps Xebec solidify its position as a leading renewable gas player by adding a 100,000 sq.
  • foot manufacturing facility in the U.S. With this acquisition, we are responding to the accelerating energy transition and the associated interest in containerized RNG and hydrogen systems.

Shawn Pearson named Chief Executive Officer and President

Retrieved on: 
Tuesday, October 12, 2021

TORONTO, Oct. 12, 2021 /PRNewswire/ - Kognitiv Corporation (the "Company"), a global leader in the rapidly expanding market for collaborative commerce, today announced that Shawn Pearson has been named Chief Executive Officer in addition to his role as President, effective October 12, 2021.

Key Points: 
  • TORONTO, Oct. 12, 2021 /PRNewswire/ - Kognitiv Corporation (the "Company"), a global leader in the rapidly expanding market for collaborative commerce, today announced that Shawn Pearson has been named Chief Executive Officer in addition to his role as President, effective October 12, 2021.
  • That experience informed my decision to join Kognitiv," said Shawn Pearson, CEO & President.
  • I look forward to serving as CEO & President to help our clients and their partners deliver value to their consumers."
  • While at Bluegreen, Shawn achieved record company EBITDA, managed multiple successful acquisitions, delivered high-valued partnerships and established a consistently high-performing organization.

bgX Selects Shortcuts To Extend On-demand Beauty Service & New E-commerce Platform Even Further

Retrieved on: 
Monday, June 10, 2019

The bgX platform allows customers to book a beauty appointment with world leading salons.

Key Points: 
  • The bgX platform allows customers to book a beauty appointment with world leading salons.
  • The new partnership with SHORTCUTS will see the bgX platform integrate, allowing customers to find nearby bgX salons and check even more availability and wider ranges of products in real time and book their favorite SHORTCUTS salons to their door.
  • The partnership with SHORTCUTS provides an even more convenient and fast service for busy people on the go."
  • For more information on SHORTCUTS and bgX, please visit https://www.shortcuts.com.au/ and go to www.bgxme.com to find out how to download the app and learn more about the platform.

bgX Selects Shortcuts To Extend On-demand Beauty Service & New E-commerce Platform Even Further

Retrieved on: 
Monday, June 10, 2019

The bgX platform allows customers to book a beauty appointment with world leading salons.

Key Points: 
  • The bgX platform allows customers to book a beauty appointment with world leading salons.
  • The new partnership with SHORTCUTS will see the bgX platform integrate, allowing customers to find nearby bgX salons and check even more availability and wider ranges of products in real time and book their favorite SHORTCUTS salons to their door.
  • The partnership with SHORTCUTS provides an even more convenient and fast service for busy people on the go."
  • For more information on SHORTCUTS and bgX, please visit https://www.shortcuts.com.au/ and go to www.bgxme.com to find out how to download the app and learn more about the platform.

Best in Beauty Combine Forces - Beauty Giant L'Oréal Confirms Partnership With bgX

Retrieved on: 
Thursday, February 14, 2019

This partnership will provide L'Oral with expanded distribution coverage of salon professional products starting with Dubai and Abu Dhabi.

Key Points: 
  • This partnership will provide L'Oral with expanded distribution coverage of salon professional products starting with Dubai and Abu Dhabi.
  • Beauty services app bgX has launched in London, Paris, Dubai and the US bringing top beauty salons to the homes or workplaces of consumers within 30 minutes, thanks to its partnership with Uber .
  • Theresa Assi, General Manager of L'Oral Professional Products Division , comments: "We are very pleased to partner with bgX, opening professional beauty experts to new customers.
  • A collaboration like this allows Uber for Business to power the bgX consumer on-demand beauty services across the Middle East faster than ever before.